Could cause temporary or reversible harm; serious harm is unlikely.
Crystallization; identified as Buprenorphine free base
| Brand name | BUPRENORPHINE HYDROCHLORIDE |
| Generic name | BUPRENORPHINE HYDROCHLORIDE |
| Active ingredient(s) | BUPRENORPHINE HYDROCHLORIDE |
| Distributed by / for | Endo USA, Malvern, PA 19355 |
| NDC | 42023-179-05 |
| Full product label | Buprenorphine HCl, CIII, Injection, 0.3 mg/mL, 5 x 1 mL Single Dose Vials per Carton, Rx Only, For Intramuscular or Intravenous use, Manufactured for: Endo USA, Malvern, PA 19355, NDC 42023-179-05 |
| Recalling firm | Par Health USA, LLC |
| Distribution | Nationwide in the USA. |
| Quantity | 46,334 units |
| Recall initiated | 2026-06-12 |
| Report date | 2026-06-24 |
| Recall completed | — |
| Recall number | D-0596-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Rochester MI United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗